Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3- and 6-month time points.

Lapusan, Simona; Yong, Agnes; Savani, Bipin N; Mohty, Mohamad

Lapusan, Simona; Yong, Agnes; Savani, Bipin N; Mohty, Mohamad.

Affiliation

Lapusan S; Saint Antoine Hospital, Pierre and Marie Curie University, Paris, France.
Yong A; Department of Haematology, SA Pathology and School of Medicine, University of Adelaide, Adelaide, SA, Australia.
Savani BN; Vanderbilt School of Medicine, Nashville, TN, USA.
Mohty M; Saint Antoine Hospital, Pierre and Marie Curie University, Paris, France.

Eur J Haematol ; 95(2): 103-12, 2015 Aug.

Article in En | MEDLINE | ID: mdl-25256677

Subject(s)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics; Disease Progression; Genes, abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology; Risk Factors

Key words

chronic myeloid leukemia; disease progression; early molecular response; therapy switch; tyrosine kinase inhibitors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Eur J Haematol Journal subject: HEMATOLOGIA Year: 2015 Type: Article Affiliation country: France

Fulltext

XML

PubMed Links

Search on Google